0001714899-23-000055.txt : 20230414 0001714899-23-000055.hdr.sgml : 20230414 20230414182713 ACCESSION NUMBER: 0001714899-23-000055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230412 FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schuth Alexander O. CENTRAL INDEX KEY: 0001724311 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 23822368 MAIL ADDRESS: STREET 1: C/O DENALI THERAPEUTICS INC. STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wf-form4_168151121787982.xml FORM 4 X0407 4 2023-04-12 0 0001714899 Denali Therapeutics Inc. DNLI 0001724311 Schuth Alexander O. C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 COFO and Secretary 0 Common Stock 2023-04-12 4 M 0 5102 5.28 A 533793 I See footnote Common Stock 2023-04-12 4 S 0 5102 25.04 D 528691 I See footnote Common Stock 2023-04-13 4 M 0 4898 5.28 A 533589 I See footnote Common Stock 2023-04-13 4 S 0 4898 25.04 D 528691 I See footnote Common Stock 130792 D Stock Option (right to buy) 5.28 2023-04-12 4 M 0 5102 0 D 2027-03-07 Common Stock 5102.0 93835 D Stock Option (right to buy) 5.28 2023-04-13 4 M 0 4898 0 D 2027-03-07 Common Stock 4898.0 88937 D Exercised shares were issued to the Schuth Family Trust. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Includes 119,156 RSUs. 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. /s/ Tyler Nielsen, by power of attorney 2023-04-14